Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mutual Alleges Mucinex Monopoly In Extended-Release Guaifenesin

This article was originally published in The Tan Sheet

Executive Summary

Mutual Pharmaceutical alleges in an antitrust suit that RB attempts to monopolize the extended-release guaifenesin OTC category with its Mucinex product. The suit says Mutual has lost “tens of millions” due to RB's failure to honor a contract to supply an “authorized generic” of the product.

Advertisement

Related Content

Reckitt Negotiating Details For Generic Mucinex It Will Provide Mutual
Reckitt Negotiating Details For Generic Mucinex It Will Provide Mutual
Congestion Continues In Private Label Mucinex Pipeline; Court Rules Against Mutual
Congestion Continues In Private Label Mucinex Pipeline; Court Rules Against Mutual
Perrigo Ships Guaifenesin/PSE Tablets, But Single-Ingredient Snags Linger
Perrigo Ships Guaifenesin/PSE Tablets, But Single-Ingredient Snags Linger
Perrigo Sets Generic Mucinex Launch After Patent Claim Decision
Adams Reinforces Mucinex Patents In Settlement Agreement With Mutual

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

PS107544

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel